Brief Research Report
Published on 18 Jun 2025
An in silico evaluation of lorlatinib as a potential therapy for novel amino acid substitutions in the tyrosine kinase domain of the ALK protein associated with cancer
in Pharmacology of Anti-Cancer Drugs
- 700 views